With artificial intelligence (AI) erupting across all aspects of life, including health care, oncology is a logical field ripe for new applications. AI is already used in cancer care and diagnosis, such as tumor identification on x-rays and pathology slides. Beyond that, emerging technology is using AI to forecast the prognosis of patients and to assess their treatment options. One unknown is how oncologists feel about this trend, which includes possibly relinquishing some control over their profession and patients.

A new study asked 204 oncologists for their views on the rapidly developing AI tools. Specifically, they were asked about ethical issues that they face regarding the deployment of AI (e.g., whether they believed that AI could be used effectively in patient-care decisions). The main issue that the researchers investigated was to what degree patients should provide explicit informed consent for the use of AI during treatment decision-making. The study appears in JAMA Network Open (doi:10.1001/jamanetworkopen.2024.4077).

随着人工智能（AI）在包括医疗保健在内的生活的各个方面爆发，肿瘤学是一个适合新应用的逻辑领域。人工智能已经应用于癌症护理和诊断，例如 X 射线和病理切片上的肿瘤识别。除此之外，新兴技术正在使用人工智能来预测患者的预后并评估他们的治疗选择。一个未知数是肿瘤学家如何看待这一趋势，其中包括可能放弃对他们的职业和患者的一些控制。

一项新研究询问了 204 名肿瘤学家对快速发展的人工智能工具的看法。具体来说，他们被问及在人工智能部署方面面临的道德问题（例如，他们是否相信人工智能可以有效地用于患者护理决策）。研究人员调查的主要问题是患者在治疗决策过程中应在多大程度上对人工智能的使用提供明确的知情同意。该研究发表在JAMA Network Open (doi:10.1001/jamanetworkopen.2024.4077) 上。